We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

30 hedge funds and large institutions have $26.3M invested in Applied Therapeutics in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

567% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 3

131% more funds holding

Funds holding: 1330 (+17)

45% more capital invested

Capital invested by funds: $18.1M → $26.3M (+$8.23M)

1.17% more ownership

Funds ownership: 12.88%14.05% (+1.2%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
30
Holders Change
+17
Holders Change %
+130.77%
% of All Funds
0.66%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
20
Increased
3
Reduced
4
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$6.44M
EMFAT
2
Emerald Mutual Fund Advisers Trust
Pennsylvania
$5.85M +$673K +71,282 +15%
KCM
3
Knoll Capital Management
Florida
$5.13M
Alkeon Capital Management
4
Alkeon Capital Management
New York
$4.39M -$7.18K -761 -0.2%
SI
5
Sofinnova Investments
California
$1.56M
ACP
6
Acuta Capital Partners
California
$912K +$783K +83,000 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$384K +$330K +34,964 New
Millennium Management
8
Millennium Management
New York
$288K -$283K -29,945 -53%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$265K +$228K +24,116 New
Northern Trust
10
Northern Trust
Illinois
$256K +$152K +16,076 +225%
BlackRock
11
BlackRock
New York
$237K -$57.9K -6,142 -22%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$227K -$1.85K -196 -0.9%
State Street
13
State Street
Massachusetts
$119K +$102K +10,803 New
EA
14
Emerald Advisers
Pennsylvania
$111K +$95.7K +10,144 New
UBS Group
15
UBS Group
Switzerland
$41K +$15.1K +1,599 +75%
California State Teachers Retirement System (CalSTRS)
16
California State Teachers Retirement System (CalSTRS)
California
$35K +$29.7K +3,144 New
AIG
17
American International Group
New York
$14K +$12K +1,274 New
Barclays
18
Barclays
United Kingdom
$11K +$9.39K +995 New
New York State Common Retirement Fund
19
New York State Common Retirement Fund
New York
$11K +$9.44K +1,000 New
JP Morgan Chase
20
JP Morgan Chase
New York
$10K +$8.45K +896 New
Bank of America
21
Bank of America
North Carolina
$10K +$8.74K +926 New
Victory Capital Management
22
Victory Capital Management
Texas
$8K +$6.66K +706 New
Morgan Stanley
23
Morgan Stanley
New York
$6K +$4.86K +515 New
Deutsche Bank
24
Deutsche Bank
Germany
$5K +$5.04K +534 New
Wells Fargo
25
Wells Fargo
California
$2K +$1.53K +162 New

APLT Hedge Fund Activity: Q3 2019 in Review

30 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q3 2019, worth a combined $26.3M — up 45% from $18.1M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new APLT positions and 3 closed out — a net gain of 17 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $783K. The largest seller was Millennium Management, cutting an estimated $283K.

  • 30 institutional investors held Applied Therapeutics (APLT) as of Q3 2019, up from 13 in Q2 2019.
  • Funds reported $26.3M of Applied Therapeutics stock for Q3 2019, up 45% quarter-over-quarter.
  • 20 funds opened new Applied Therapeutics positions in Q3 2019 and 3 closed out, a net change of +17 holders.
  • The largest Applied Therapeutics buyer in Q3 2019 was Acuta Capital Partners, an estimated $783K added.
  • The largest Applied Therapeutics seller in Q3 2019 was Millennium Management, an estimated $283K sold.

Based on aggregated 13F filings for Q3 2019.